Chronic Kidney Disease (CKD) Drugs Market: Global Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Chronic Kidney Disease (CKD) Drugs Market: By Drug Class (Antihypertensive, ACE Inhibitors, Angiotensin-II Receptor Blockers, Beta Blockers, Calcium Channel Blockers, Diuretics, Anemia Treatment Drugs, Antihyperlipidemic Drugs Others) Route of Administration (Oral, Parenteral Others) Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

1. Executive Summary
2. Global Chronic Kidney Disease (CKD) Drugs Market Introduction
2.1. Global Chronic Kidney Disease (CKD) Drugs Market – Taxonomy
2.2. Global Chronic Kidney Disease (CKD) Drugs Market –Definitions
2.2.1. By  Drug Class
2.2.2. By Route of Administration
2.2.3. By Distribution Channel
2.2.4. By Region
3. Global Chronic Kidney Disease (CKD) Drugs Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Chronic Kidney Disease (CKD) Drugs Market Dynamic Factors – Impact Analysis
3.6. Global Chronic Kidney Disease (CKD) Drugs Market – Competition Landscape
4. Global Chronic Kidney Disease (CKD) Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Chronic Kidney Disease (CKD) Drugs Market, By Drug Class, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
5.1. Antihypertensive
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. ACE Inhibitors
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Angiotensin-II Receptor Blockers
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Beta Blockers
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Calcium Channel Blockers
5.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Diuretics
5.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Anemia Treatment Drugs
5.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
5.8. Antihyperlipidemic Drugs
5.8.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.8.3. Market Opportunity Analysis
5.9. Others
5.9.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.9.3. Market Opportunity Analysis
6. Global Chronic Kidney Disease (CKD) Drugs Market, By Route of Administration, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
6.1. Oral
6.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Parenteral
6.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Others
6.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global Chronic Kidney Disease (CKD) Drugs Market Forecast, By Distribution Channel, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
7.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. Global Chronic Kidney Disease (CKD) Drugs Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
8.1. North America
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Chronic Kidney Disease (CKD) Drugs Market – Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Region, 2022 – 2028
9. North America Chronic Kidney Disease (CKD) Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
9.1.  Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Antihypertensive
9.1.2. ACE Inhibitors
9.1.3. Angiotensin-II Receptor Blockers
9.1.4. Beta Blockers
9.1.5. Calcium Channel Blockers
9.1.6. Diuretics
9.1.7. Anemia Treatment Drugs
9.1.8. Antihyperlipidemic Drugs
9.1.9. Others
9.2. Route of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Oral
9.2.2. Parenteral
9.2.3. Others
9.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. USA
9.4.2. Canada
9.5. North America Chronic Kidney Disease (CKD) Drugs Market – Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel and Country, 2022 – 2028
9.6. North America Chronic Kidney Disease (CKD) Drugs Market Dynamics – Trends
10. Europe Chronic Kidney Disease (CKD) Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
10.1.  Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Antihypertensive
10.1.2. ACE Inhibitors
10.1.3. Angiotensin-II Receptor Blockers
10.1.4. Beta Blockers
10.1.5. Calcium Channel Blockers
10.1.6. Diuretics
10.1.7. Anemia Treatment Drugs
10.1.8. Antihyperlipidemic Drugs
10.1.9. Others
10.2. Route of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Oral
10.2.2. Parenteral
10.2.3. Others
10.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Rest of Europe
10.5. Europe Chronic Kidney Disease (CKD) Drugs Market – Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel and Country, 2022 – 2028
10.6. Europe Chronic Kidney Disease (CKD) Drugs Market Dynamics – Trends
11. Asia-Pacific Chronic Kidney Disease (CKD) Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
11.1.  Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Antihypertensive
11.1.2. ACE Inhibitors
11.1.3. Angiotensin-II Receptor Blockers
11.1.4. Beta Blockers
11.1.5. Calcium Channel Blockers
11.1.6. Diuretics
11.1.7. Anemia Treatment Drugs
11.1.8. Antihyperlipidemic Drugs
11.1.9. Others
11.2. Route of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Oral
11.2.2. Parenteral
11.2.3. Others
11.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Chronic Kidney Disease (CKD) Drugs Market – Opportunity Analysis Index, By Drug Class, By Route of Administration , By Distribution Channel and Country, 2022 – 2028
11.6. Asia-Pacific Chronic Kidney Disease (CKD) Drugs Market Dynamics – Trends
12. Latin America Chronic Kidney Disease (CKD) Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
12.1.  Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Antihypertensive
12.1.2. ACE Inhibitors
12.1.3. Angiotensin-II Receptor Blockers
12.1.4. Beta Blockers
12.1.5. Calcium Channel Blockers
12.1.6. Diuretics
12.1.7. Anemia Treatment Drugs
12.1.8. Antihyperlipidemic Drugs
12.1.9. Others
12.2. Route of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Oral
12.2.2. Parenteral
12.2.3. Others
12.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Rest of Latin America
12.5. Latin America Chronic Kidney Disease (CKD) Drugs Market – Opportunity Analysis Index, By Drug Class, By Route of Administration , By Distribution Channel and Country, 2022 – 2028
12.6. Latin America Chronic Kidney Disease (CKD) Drugs Market Dynamics – Trends
13. Middle East and Africa Chronic Kidney Disease (CKD) Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
13.1.  Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Antihypertensive
13.1.2. ACE Inhibitors
13.1.3. Angiotensin-II Receptor Blockers
13.1.4. Beta Blockers
13.1.5. Calcium Channel Blockers
13.1.6. Diuretics
13.1.7. Anemia Treatment Drugs
13.1.8. Antihyperlipidemic Drugs
13.1.9. Others
13.2. Route of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Oral
13.2.2. Parenteral
13.2.3. Others
13.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Chronic Kidney Disease (CKD) Drugs Market – Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel and Country, 2022 – 2028
13.6. MEA Chronic Kidney Disease (CKD) Drugs Market Dynamics – Trends
14. Competition Landscape 
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. AbbVie, Inc.
14.2.2. Akebia Therapeutics
14.2.3. Allergan plc.
14.2.4. Amgen Inc.
14.2.5. Ardelyx, Inc.
14.2.6. AstraZeneca plc
14.2.7. F. Hoffmann-La Roche Ltd.
14.2.8. FibroGen
14.2.9. GlaxoSmithKline plc.
14.2.10. Johnson & Johnson
14.2.11. Kissei Pharmaceutical Co., Ltd.
14.2.12. Pfizer, Inc.
14.2.13. Reata Pharmaceuticals, Inc.
14.2.14. Sanofi S.A.
14.2.15. Teva Pharmaceutical Industries Ltd.
15. Research Methodology
16. Key Assumptions and Acronyms

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Company Profile

  • AbbVie, Inc.
  • Akebia Therapeutics
  • Allergan plc.
  • Amgen Inc.
  • Ardelyx, Inc.
  • AstraZeneca plc
  • Hoffmann-La Roche Ltd.
  • FibroGen
  • GlaxoSmithKline plc.
  • Johnson & Johnson
  • Kissei Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Reata Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

Description

1. Executive Summary
2. Global Chronic Kidney Disease (CKD) Drugs Market Introduction
2.1. Global Chronic Kidney Disease (CKD) Drugs Market – Taxonomy
2.2. Global Chronic Kidney Disease (CKD) Drugs Market –Definitions
2.2.1. By  Drug Class
2.2.2. By Route of Administration
2.2.3. By Distribution Channel
2.2.4. By Region
3. Global Chronic Kidney Disease (CKD) Drugs Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Chronic Kidney Disease (CKD) Drugs Market Dynamic Factors – Impact Analysis
3.6. Global Chronic Kidney Disease (CKD) Drugs Market – Competition Landscape
4. Global Chronic Kidney Disease (CKD) Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Chronic Kidney Disease (CKD) Drugs Market, By Drug Class, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
5.1. Antihypertensive
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. ACE Inhibitors
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Angiotensin-II Receptor Blockers
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Beta Blockers
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Calcium Channel Blockers
5.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Diuretics
5.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Anemia Treatment Drugs
5.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
5.8. Antihyperlipidemic Drugs
5.8.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.8.3. Market Opportunity Analysis
5.9. Others
5.9.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.9.3. Market Opportunity Analysis
6. Global Chronic Kidney Disease (CKD) Drugs Market, By Route of Administration, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
6.1. Oral
6.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Parenteral
6.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Others
6.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global Chronic Kidney Disease (CKD) Drugs Market Forecast, By Distribution Channel, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
7.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. Global Chronic Kidney Disease (CKD) Drugs Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
8.1. North America
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Chronic Kidney Disease (CKD) Drugs Market – Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Region, 2022 – 2028
9. North America Chronic Kidney Disease (CKD) Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
9.1.  Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Antihypertensive
9.1.2. ACE Inhibitors
9.1.3. Angiotensin-II Receptor Blockers
9.1.4. Beta Blockers
9.1.5. Calcium Channel Blockers
9.1.6. Diuretics
9.1.7. Anemia Treatment Drugs
9.1.8. Antihyperlipidemic Drugs
9.1.9. Others
9.2. Route of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Oral
9.2.2. Parenteral
9.2.3. Others
9.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. USA
9.4.2. Canada
9.5. North America Chronic Kidney Disease (CKD) Drugs Market – Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel and Country, 2022 – 2028
9.6. North America Chronic Kidney Disease (CKD) Drugs Market Dynamics – Trends
10. Europe Chronic Kidney Disease (CKD) Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
10.1.  Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Antihypertensive
10.1.2. ACE Inhibitors
10.1.3. Angiotensin-II Receptor Blockers
10.1.4. Beta Blockers
10.1.5. Calcium Channel Blockers
10.1.6. Diuretics
10.1.7. Anemia Treatment Drugs
10.1.8. Antihyperlipidemic Drugs
10.1.9. Others
10.2. Route of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Oral
10.2.2. Parenteral
10.2.3. Others
10.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Rest of Europe
10.5. Europe Chronic Kidney Disease (CKD) Drugs Market – Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel and Country, 2022 – 2028
10.6. Europe Chronic Kidney Disease (CKD) Drugs Market Dynamics – Trends
11. Asia-Pacific Chronic Kidney Disease (CKD) Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
11.1.  Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Antihypertensive
11.1.2. ACE Inhibitors
11.1.3. Angiotensin-II Receptor Blockers
11.1.4. Beta Blockers
11.1.5. Calcium Channel Blockers
11.1.6. Diuretics
11.1.7. Anemia Treatment Drugs
11.1.8. Antihyperlipidemic Drugs
11.1.9. Others
11.2. Route of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Oral
11.2.2. Parenteral
11.2.3. Others
11.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Chronic Kidney Disease (CKD) Drugs Market – Opportunity Analysis Index, By Drug Class, By Route of Administration , By Distribution Channel and Country, 2022 – 2028
11.6. Asia-Pacific Chronic Kidney Disease (CKD) Drugs Market Dynamics – Trends
12. Latin America Chronic Kidney Disease (CKD) Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
12.1.  Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Antihypertensive
12.1.2. ACE Inhibitors
12.1.3. Angiotensin-II Receptor Blockers
12.1.4. Beta Blockers
12.1.5. Calcium Channel Blockers
12.1.6. Diuretics
12.1.7. Anemia Treatment Drugs
12.1.8. Antihyperlipidemic Drugs
12.1.9. Others
12.2. Route of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Oral
12.2.2. Parenteral
12.2.3. Others
12.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Rest of Latin America
12.5. Latin America Chronic Kidney Disease (CKD) Drugs Market – Opportunity Analysis Index, By Drug Class, By Route of Administration , By Distribution Channel and Country, 2022 – 2028
12.6. Latin America Chronic Kidney Disease (CKD) Drugs Market Dynamics – Trends
13. Middle East and Africa Chronic Kidney Disease (CKD) Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
13.1.  Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Antihypertensive
13.1.2. ACE Inhibitors
13.1.3. Angiotensin-II Receptor Blockers
13.1.4. Beta Blockers
13.1.5. Calcium Channel Blockers
13.1.6. Diuretics
13.1.7. Anemia Treatment Drugs
13.1.8. Antihyperlipidemic Drugs
13.1.9. Others
13.2. Route of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Oral
13.2.2. Parenteral
13.2.3. Others
13.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Chronic Kidney Disease (CKD) Drugs Market – Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel and Country, 2022 – 2028
13.6. MEA Chronic Kidney Disease (CKD) Drugs Market Dynamics – Trends
14. Competition Landscape 
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. AbbVie, Inc.
14.2.2. Akebia Therapeutics
14.2.3. Allergan plc.
14.2.4. Amgen Inc.
14.2.5. Ardelyx, Inc.
14.2.6. AstraZeneca plc
14.2.7. F. Hoffmann-La Roche Ltd.
14.2.8. FibroGen
14.2.9. GlaxoSmithKline plc.
14.2.10. Johnson & Johnson
14.2.11. Kissei Pharmaceutical Co., Ltd.
14.2.12. Pfizer, Inc.
14.2.13. Reata Pharmaceuticals, Inc.
14.2.14. Sanofi S.A.
14.2.15. Teva Pharmaceutical Industries Ltd.
15. Research Methodology
16. Key Assumptions and Acronyms

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX